BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38491867)

  • 1. Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
    Buck SAJ; Talebi Z; Drabison T; Jin Y; Gibson AA; Hu P; de Bruijn P; de Ridder CMA; Stuurman D; Hu S; van Weerden WM; Koolen SLW; de Wit R; Sparreboom A; Mathijssen RHJ; Eisenmann ED
    Int J Cancer; 2024 Jul; 155(2):314-323. PubMed ID: 38491867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
    Buck SAJ; Van Hemelryk A; de Ridder C; Stuurman D; Erkens-Schulze S; van 't Geloof S; Teubel WJ; Koolen SLW; Martens-Uzunova ES; van Royen ME; de Wit R; Mathijssen RHJ; van Weerden WM
    Mol Cancer Ther; 2024 May; 23(5):711-720. PubMed ID: 38030379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
    Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
    Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pre-incubation with OATP1B1 and OATP1B3 inhibitors potentiates inhibitory effects in physiologically relevant sandwich-cultured primary human hepatocytes.
    Farasyn T; Pahwa S; Xu C; Yue W
    Eur J Pharm Sci; 2021 Oct; 165():105951. PubMed ID: 34311070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearance.
    Lee HH; Leake BF; Teft W; Tirona RG; Kim RB; Ho RH
    Mol Cancer Ther; 2015 Apr; 14(4):994-1003. PubMed ID: 25695959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with proteasome inhibitor bortezomib decreases organic anion transporting polypeptide (OATP) 1B3-mediated transport in a substrate-dependent manner.
    Alam K; Farasyn T; Crowe A; Ding K; Yue W
    PLoS One; 2017; 12(11):e0186924. PubMed ID: 29107984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic Effects of Different Models of Nonalcoholic Fatty Liver Disease in Transgenic Humanized OATP1B Mice.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; White LA; Graf TN; Oberlies NH; Clarke JD
    Drug Metab Dispos; 2024 Apr; 52(5):355-367. PubMed ID: 38485280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).
    Borgmann H; Lallous N; Ozistanbullu D; Beraldi E; Paul N; Dalal K; Fazli L; Haferkamp A; Lejeune P; Cherkasov A; Gleave ME
    Eur Urol; 2018 Jan; 73(1):4-8. PubMed ID: 28851578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
    Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rifampin- and Silymarin-Mediated Pharmacokinetic Interactions of Exogenous and Endogenous Substrates in a Transgenic OATP1B Mouse Model.
    Bechtold BJ; Lynch KD; Oyanna VO; Call MR; Graf TN; Oberlies NH; Clarke JD
    Mol Pharm; 2024 May; 21(5):2284-2297. PubMed ID: 38529622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of Weak Organic Anion-Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans.
    Zhang Y; Holenarsipur VK; Kandoussi H; Zeng J; Mariappan TT; Sinz M; Shen H
    Drug Metab Dispos; 2020 Oct; 48(10):841-848. PubMed ID: 32723847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford ED; Kopyltsov E; Park CH; Alekseev B; Montesa-Pino Á; Ye D; Parnis F; Cruz F; Tammela TLJ; Suzuki H; Utriainen T; Fu C; Uemura M; Méndez-Vidal MJ; Maughan BL; Joensuu H; Thiele S; Li R; Kuss I; Tombal B;
    N Engl J Med; 2022 Mar; 386(12):1132-1142. PubMed ID: 35179323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of SLCO1B3 drives taxane resistance in prostate cancer.
    de Morrée ES; Böttcher R; van Soest RJ; Aghai A; de Ridder CM; Gibson AA; Mathijssen RH; Burger H; Wiemer EA; Sparreboom A; de Wit R; van Weerden WM
    Br J Cancer; 2016 Sep; 115(6):674-81. PubMed ID: 27537383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS trial.
    Smith MR; Hussain M; Saad F; Fizazi K; Sternberg CN; Crawford D; Manarite J; Muslin D; Farrington T; Tombal B
    Future Oncol; 2022 Jul; 18(21):2585-2597. PubMed ID: 35656777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial.
    Shore N; Zurth C; Fricke R; Gieschen H; Graudenz K; Koskinen M; Ploeger B; Moss J; Prien O; Borghesi G; Petrenciuc O; Tammela TL; Kuss I; Verholen F; Smith MR; Fizazi K
    Target Oncol; 2019 Oct; 14(5):527-539. PubMed ID: 31571095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darolutamide: A Review in Metastatic Hormone-Sensitive Prostate Cancer.
    Lee A
    Target Oncol; 2023 Sep; 18(5):793-800. PubMed ID: 37542594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OATP1B3 Expression and Function is Modulated by Coexpression with OCT1, OATP1B1, and NTCP.
    Zhang Y; Ruggiero M; Hagenbuch B
    Drug Metab Dispos; 2020 Aug; 48(8):622-630. PubMed ID: 32482756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preincubation With Everolimus and Sirolimus Reduces Organic Anion-Transporting Polypeptide (OATP)1B1- and 1B3-Mediated Transport Independently of mTOR Kinase Inhibition: Implication in Assessing OATP1B1- and OATP1B3-Mediated Drug-Drug Interactions.
    Farasyn T; Crowe A; Hatley O; Neuhoff S; Alam K; Kanyo J; Lam TT; Ding K; Yue W
    J Pharm Sci; 2019 Oct; 108(10):3443-3456. PubMed ID: 31047942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. OATP1B3-1B7, a novel organic anion transporting polypeptide, is modulated by FXR ligands and transports bile acids.
    Malagnino V; Hussner J; Issa A; Midzic A; Meyer Zu Schwabedissen HE
    Am J Physiol Gastrointest Liver Physiol; 2019 Dec; 317(6):G751-G762. PubMed ID: 31509437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional characterization for polymorphic organic anion transporting polypeptides (OATP/SLCO1B1, 1B3, 2B1) of monkeys recombinantly expressed with various OATP probes.
    Takahashi T; Uno Y; Yamazaki H; Kume T
    Biopharm Drug Dispos; 2019 Feb; 40(2):62-69. PubMed ID: 30652318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.